Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - Haematological malignancies

892MO - High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with HIV-related lymphoma

Date

18 Sep 2020

Session

Mini Oral - Haematological malignancies

Topics

Cytotoxic Therapy

Tumour Site

Lymphomas

Presenters

Marina Popova

Citation

Annals of Oncology (2020) 31 (suppl_4): S590-S598. 10.1016/annonc/annonc261

Authors

M. Popova1, I. Tsygankov2, Y. Rogacheva2, K. Lepik2, Y. Zalylov2, L. Stelmah2, V. Baykov2, S. Bondarenko2, N. Mikhaylova2

Author affiliations

  • 1 Hematology, Raisa Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, First Pavlov State Medical University of Saint-Petersburg, 197022 - Saint Petersburg/RU
  • 2 Hematology, Raisa Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, First Pavlov State Medical University of Saint-Petersburg, 197022 - Санкт-Петербург/RU

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 892MO

Background

The number of prospective matched case-controlled studies to prove the safety and efficacy of autologous stem cell transplantation (ASCT) in HIV-related lymphoma is limited.

Methods

Between January 2016 and January 2020, twelve patients with HIV-related lymphoma who have undergone ASCT were included in this prospective matched case-control study (study group, n=12). Forty eight non-HIV-infected patients were enrolled to the control group (n=48, 1:4). The median age was 34 (19-66) y.o. The underlying diseases in the study group were Hodgkin lymphoma (HL) n=7 (58,3%) and non-Hodgkin lymphoma (NHL) n=5 (41,7%), complete remission at the moment of ASCT – 66,7%. Conditioning regimen was BEAM with BCNU replacement by Bendamustine 160 mg/m2/day at D-7, D-6. HIV viral load was undetectable; the median number of CD4+ cells was 471,5 (210-715) cells/mcl; all patients were on anti-retroviral therapy (ART). The median follow up time was 16 (1-43) months.

Results

The 2-year overall survival (OS) (n=60) was 90%; 91,7% in the study group and 89,9% in the control group, and this was not significantly different between the groups (P= 0,763). Progression-free survival (PFS) at 2 years in the study group was 75%, and was not significantly different to the control group (70,8%; P=0,777). Time to progression (TTP) at 2 years was 14,6% in the study group and 16,7% in the control group (P=0,643). Complete remission at the moment of ASCT improved PFS (P =0,03) and TTP (P =0,044) in the whole group. The median time for recovery of leukocytes, neutrophils, and platelets was D+14,5 (10-25), D+17 (12-30), D+15,5 (11-31), respectively, in the study group and D+14 (10-22), D+15 (10-23), D+15 (8-31) in the control group. Neutrophil recovery was significantly delayed in study group (P=0,04). There was no difference in the rate of organ toxicity according to CTCAE. The transplant-related mortality (TRM) at 2 years was 8,3% in the study group and 6,2% in the control group (P=0,8).

Conclusions

Two-year overall survival in patients with HIV-related lymphoma was 91.7%, PFS was 75%, TTP was 14,6% and TRM was 8,3% and did not differ significantly from the control group. Only neutrophil recovery was significantly delayed after ASCT in patients with HIV-related lymphoma. Our data provide further evidence that ASCT is a safe and effective approach for patients with HIV-related lymphoma.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.